Endo, Jubilant Expand Oncology Pact

Jubilant Biosys Ltd., a subsidiary of Jubilant Organosys Ltd., and Endo Pharmaceuticals have expanded their drug discovery partnership in oncology, following the delivery of an early stage milestone.

Jubilant focuses on delivering preclinical oncology candidates while Endo owns the late-stage development and commercialization rights for any molecules discovered. Jubilant receives research funding and success-based development and commercialization milestones.

Sri Mosur, chief executive officer and president of Global Drug Discovery & Development at Jubilant Biosys, said, “We are pleased that we could deliver early success to the discovery portfolio efforts at Endo Pharmaceuticals and this expansion is a testimony to Jubilant’s focus in building world class oncology capabilities, among other therapeutic areas. This collaboration further reinforces the concept of globally leveraged R&D that creates a platform for scientists from Endo and Jubilant to collaborate in finding affordable remedies for cancer patients worldwide.”

“We have been impressed by the quality of the science and the progress made to date by the Jubilant team on our ongoing oncology discovery program, said Dr. Ivan Gergel, M.D, executive vice president of R&D at Endo Pharmaceuticals. “Expanding our relationship in this important therapeutic area is consistent with our strategy of building Endo’s pipeline using a virtual discovery approach, in conjunction with our in-licensing efforts.”